MAINZ, Germany, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, âBioNTechâ or âthe Companyâ), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020. âWe made significant progress in the second quarter toward our goal of advancing our oncology programs and toward bringing a COVID-19 vaccine to market as quickly as possible. I am incredibly proud of our team, who has worked tirelessly to initiate our BNT162 Phase 2b/3 trial in record time and put us in a position to seek regulatory review as early as October of this year, if our trials are successful,â said Ugur Sahin, BioNTechâs CEO and Co-founder. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. The program is partnered with Genmab. All agreements are subject to clinical success and regulatory approval. Quartalszahlen-0,1715 EUR: Q4 2020: 06.04.2021 (e)* Quartalszahlen: 1,7343 EUR: Q1 2021: 18.05.2021 (e)* Quartalszahlen: 2,5251 EUR: Q2 2021: 17.08.2021 (e)* Quartalszahlen⦠BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020. United States international:              +1 646 741 3167United States domestic (toll-free):   +1 877 870 9135Germany:                     +49 692 2222 625. 11.08.2020 08:11 Uhr - Autor: Michael Barck auf Twitter Heute wird BioNTech Quartalszahlen vorlegen. Additional objectives include evaluation of immunogenicity and clinical efficacy. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 08:00 a.m. EDT (2:00 p.m. CET) to report its financial results and provide a corporate update on the third quarter 2020. Released data from the ongoing U.S. * Foreign exchange differences on a cumulative basis are either shown as finance income or expenses and might switch between those two positions during the year-to-date reporting periods. The revenues from other sales transactions increased due to increased orders and include sales of diagnostic products, peptides, retroviral vectors for clinical supply and development and manufacturing services sold to third-party customers. Lesen Sie jetzt âKurz vor Antrag für Impfstoff: Biontech legt Zahlen vorâ. BNT221 (NEO-PTC-01) â Initiation of a Phase 1 dose escalation trial of BNT221 is expected in 2H 2020 for the treatment of metastatic melanoma in patients who are refractory or unresponsive to checkpoint inhibitors. Die Corona-Infektionszahlen sind ⦠Für die neun Monate bis zum 30. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. As a monotherapy and in combination with atezolizumab, RO7198457 (BNT122/RG6180) was observed to have a manageable safety profile and to induce significant levels of neoantigen-specific immune responses, even in late-stage, heavily pre-treated patients. BNT122 â BioNTech and Genentech reported a data update for the Phase 1a and 1b trial in multiple solid tumors in June 2020 as part of the American Association for Cancer Research (AACR) Virtual Annual Meeting II. For any other questions, please use our contact form at connect.biontech.de. BioNTech hat in dieser Woche die Übernahme von Neon Therapeutics abgeschlossen. ADRs) Quartalszahlen: 30.03.21: BioNTech SE (spons. Tesla, BioNTech, Varta - die meistgehandelten Aktien des Tages 22.10.2020 | 15:44 Johanna Krämer blickt in dieser Sendung auf die meistgehandelten Werte beim Onlinebroker Flatex. You should review the risks and uncertainties described under the heading âRisk Factorsâ in BioNTechâs Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 31, 2020 and in subsequent filings made by BioNTech with the SEC, which are available on the SECâs website at https://www.sec.gov/. 2020 Guidance: As a result of increased spending related to BNT162, BioNTech now expects net cash used in operating activities to be between â¬450M and â¬600M. ET (2:00 p.m. CET) to report its financial results for the quarter ended June 30, 2020 and provide a corporate update. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call. BNT111 â On July 30, BioNTech announced the publication of interim Phase 1 data for BNT111, the Companyâs lead mRNA-based FixVac cancer vaccine program, in, BNT111 â On July 31, BioNTech and Regeneron Pharmaceuticals, Inc. announced a strategic collaboration to jointly conduct a randomized Phase 2 study for the treatment of melanoma that has progressed after prior PD-1 blockade, utilizing BNT111 FixVac and Regeneronâs Libtayo. Studie in "Rekordzeit" Biontech peilt weiter Impfstoffzulassung im Oktober an - For the period of six months ended June 30, 2020, total general and administrative expenses were â¬34.6 million, compared to â¬23.9 million for the comparative prior year period. Dienstag, 11.08.2020 14:16 von dpa-AFX | Aufrufe: 1210 Biontech peilt weiter Impfstoffzulassung im Oktober an - Quartalszahlen Verschiedene Medikamente in Tablettenform (Symbolbild). BioNTech: Die Quartalszahlen sind da! multilang-release. Received Fast Track designation for BNT162b1 and BNT162b2 from the U.S. Food and Drug Administration (FDA). On July 22, 2020, BioNTech announced the terms of a rights offering of rights to subscribe for ordinary shares, including ordinary shares represented by ADSs, extended to holders of its ordinary shares and ADSs. To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID: Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. During the second quarter, BioNTech completed the acquisition of Neon Therapeutics, Inc. BioNTech continues to integrate the new subsidiary, based in Cambridge, Massachusetts, which serves as BioNTechâs U.S. headquarters. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companyâs website for 30 days following the call. In Q2 2020 BioNTech received an aggregate of â¬216.7 million ($236.0 million) in non-refundable upfront payments from the BNT162 collaboration agreements and ⦠Net Loss: Net loss was â¬88.3 million for the three months ended June 30, 2020, compared to â¬50.1 million for the three months ended June 30, 2019. BNT311 â BioNTech expects to provide a data update in 2H 2020, which will include dose-escalation data from the Phase 1/2 trial in multiple solid tumors for GEN1042/BNT311 (PD-L1x4-1BB). Investor RelationsSylke Maas, Ph.D. VP Investor Relations & Business Strategy Tel: +49 (0)6131 9084 1074 E-mail: Investors@biontech.deÂ, Media RelationsJasmina AlatovicSenior Manager Global External Communications Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 E-mail: Media@biontech.de, Interim Condensed Consolidated Statements of Financial Position, Interim Condensed Consolidated Statements of Operations. For the period of six months ended June 30, 2020, total research and development expenses were â¬160.3 million, compared to â¬110.6 million for the comparative prior year period. Unter dem Strich hat Biontech deshalb Verlust gemacht: Minus 210,0 Millionen Euro im dritten Quartal, nach einem Verlust von 30,1 Millionen Euro im Vorjahresquartal, stehen in den Büchern. This trial will be a multi-site, open-label, Phase 2, randomized trial to compare the efficacy of RO7198457 (BNT122/ RG6180) versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage 2/3 rectal cancer, or Stage 2 (high risk)/Stage 3 colon cancer. © 2021 GlobeNewswire, Inc. All Rights Reserved. BioNTech ist heute ganz schön ordentlich gefallen. On June 29, 2020, BioNTech announced the signing of a private investment of â¬223.9 million ($250.7 million, On June 11, 2020, the European Investment Bank (EIB) and BioNTech entered into a â¬100.0 million ($112.0 million. In addition, from the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed to our research and development expenses. Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube. Initiated a Phase 2b/3 study for BNT162b2 in up to 30,000 participants aged 18 to 85 years at approximately 120 sites globally; if successful, BioNTech and Pfizer plan to file for market authorization or regulatory approval as early as October 2020. Biontech peilt weiter Impfstoffzulassung im Oktober an - Quartalszahlen Nachrichtenagentur: dpa-AFX | 11.08.2020, 14:16 | 1110 | 0 | 0 im Vorjahreszeitraum. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTechâs control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Dienstag 10.11.2020 21:52 - Finanztreff.de. BioNTech SE An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 For questions on logistics, handling or other issues: service@biontech.de. ET (2:00 p.m. CET). ADRs) Quartalszahlen: 10.05.21: BioNTech SE (spons. Im aktuellen Geschäftsjahr muss wiederum ⦠On July 27, 2020, BioNTech announced the closing of an underwritten offering of 5,500,000 American Depositary Shares (âADSsâ), each representing one of BioNTechâs ordinary shares, at a public offering price of $93.00 per ADS, for gross proceeds of â¬456.8 million ($511.5 million. Bald kommen die Quartalszahlen (6.4) - meint ihr ein Einstieg lohnt sich nun? ... September 2020 ergab sich ⦠Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was â¬41.8 million for the three months ended June 30, 2020, compared to â¬25.8 million for the three months ended June 30, 2019. Interest expense related to lease liability, Basic & diluted, loss per share for the period attributable to equity holders of the parent**. As a result of increased spending related to BNT162, BioNTech now expects net cash used in operating activities and for purchases of property and equipment to be between â¬450 million and â¬600 million in the full year 2020. Phase 1/2 placebo-controlled, observer-blinded clinical trial, evaluating nucleoside-modified messenger RNA vaccine candidate (BNT162b1) in 45 subjects, and data from the ongoing Germany trial in 60 subjects. September 2020 endenden Quartals ⦠Nachrichtenquelle: 4investors | 11.05.2020, 14:17 | 511 | 0 | 0 Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. Mit vielversprechenden Nachrichten zu seinem Impfstoff hat Biontech große Hoffnungen im Kampf gegen die Corona-Pandemie geschürt. Diese hätten nicht viel Neues parat gehabt, schrieb Analyst Cory Kasimovâ¦. BioNTech (ADRs Termine: Hier finden Sie die Termine-Seite für den Wert BioNTech (ADRs Historische Entwicklung von Quartalszahlen der BioNTech Aktie (WKN: A2PSR2 / ISIN: US09075V1026) aus dem Sektor Biotechnologie, Informationen von boerse.de Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. BNT113 â Planned initiation of a potentially registrational Phase 2 trial in HPV16+ head and neck cancer expected in 2H 2020. BioNTech anticipates that existing cash and cash equivalents, the net proceeds from the recent underwritten offering and the expected net proceeds from the private investment announced in June 2020 will enable the Company to fund operating expenses and capital requirements through at least the next 24 months. BNT122 â Two Phase 2 clinical trials are planned in the adjuvant setting. Am 27. 08.05.2020 BNT411 â On July 8, the first patient was dosed in a Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC). Participants may also access the slides and the webcast of the conference call via the âEvents & Presentationsâ page of the Investor Relations section of the Companyâs website at https://biontech.de/. BioNTech Neutral 10.11.2020 21:52:55 NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Biontech nach Quartalszahlen von 68 ⦠... Darüber hinaus verkündet das Unternehmen morgen seine Quartalszahlen für Q3 2020. While the preclinical focus has mainly been on ovarian cancer, patients with uterine, testicular, lung and gastric cancers may also be enrolled. For more information, please visit www.BioNTech.de. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. Die US-Bank JPMorgan hat das Kursziel für Biontech nach Quartalszahlen von 68 auf 90 US-Dollar angehoben, die Einstufung aber auf 'Neutral' belassen. Quartalszahlen von Biontech kurz vor Antrag für Corona-Impfstoff. 1 All amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of June 30, 2020. General and Administrative Expenses: General and administrative expenses were â¬18.8 million for the three months ended June 30, 2020, compared to â¬14.6 million for the three months ended June 30, 2019. © 2021 GlobeNewswire, Inc. All Rights Reserved. To participate in the conference call, please dial the following numbers 15-20 minutes prior to the start of the call and provide the Conference ID: 1963889. In Q2 2020 BioNTech received an aggregate of â¬216.7 million ($236.0 million) in non-refundable upfront payments from the BNT162 collaboration agreements and equity investments with Pfizer and Fosun Pharma. https://edge.media-server.com/mmc/p/jqhpczzu. For the period of six months ended June 30, 2020, total net loss was â¬141.7 million, compared to â¬90.8 million for the comparative prior year period. 10.11.2020 - 05:50 ... zu seinem Corona-Impfstoff legt das Mainzer Pharmaunternehmen Biontech ⦠Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. The slide presentation and audio of the webcast will be available via the following link: https://edge.media-server.com/mmc/p/jqhpczzu. The ADS rights exercise period expires at 12:01 a.m. (New York City time) on August 14, 2020 and the ordinary share rights exercise period expires one minute after 11:59 p.m. (Mainz, Germany time) on August 14, 2020. BNT122 â BioNTech expects to provide an enrollment update from the Phase 2 trial (IMCODE-001) in first line melanoma in 2H 2020 with an interim data update anticipated in 2H 2021. We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases The increase was mainly influenced by higher expenses for purchased management consulting and legal services as well as an increase in headcount leading to higher wages, benefits and social security expenses. Deshalb steigt die Anspannung vor dem 11.08.2020 â an diesem Tag will BioNTech die Zahlen zum Q2 veröffentlichen, die keine großen Überraschungen enthalten sollten, da BioNTech bisher ânurâ forscht und noch keine nenneswerten Umsätze erzielt â plangemäß. Biontech konnte im Vergleich zum Vorjahr seinen Umsatz zwar steigern, ... Biontech legt die Quartalszahlen offen. BNT211 â Initiation of a Phase 1/2a open-label, multi-site dose escalation and dose expansion basket trial with or without a CLDN6 CARVac immunotherapy is expected in 2H 2020. About BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Die Cash-Bestand belief sich zum 30. von Finanztreff.de, 11.08.2020, 14:36 Uhr Aktien BioNTech Finanzen. Modernaâs Coronavirus Treatment Transforms Body Into Vaccine ⦠11.08.2020 - 14:36 | Quelle: finanztreff | Lesedauer etwa 3 min. For more information, please visit www.BioNTech.de Â. The first adjuvant Phase 2 study is currently recruiting for patients and first patient dosing is expected in 2H 2020. Pfizer präsentiert in der voraussichtlich am 02.02.2021 stattfindenden Finanzkonferenz das Zahlenwerk zum jüngsten Quartal, welches am 31.12.2020 endete. The trial is designed to evaluate the efficacy and safety of RO7198457 (BNT122/RG6180) plus atezolizumab compared with atezolizumab alone in patients with early and adjuvant stage non-small-cell lung cancer (NSCLC). The revenue from collaboration agreements overall increased due to the recognition of revenue from our new collaboration agreements signed with Pfizer and Fosun Pharma as part of the Companyâs BNT162 vaccine program against COVID-19. BioNTech Aktie Klingelt morgen mit den Quartalszahlen der Wecker? Certain holders irrevocably agreed not to transfer or exercise their rights in the rights offering, and the shares underlying those rights were offered in the underwritten offering. âIn addition, we have significantly strengthened our balance sheet, providing financial resources to advance our broad pipeline of novel immunotherapies targeting oncology and infectious disease.â Â, Second Quarter 2020 and Subsequent Updates, Individualized neoantigen specific immunotherapy (iNeST), Next-generation checkpoint immunomodulators. RO7198457 (BNT122/RG6180) is partnered with Genentech. BNT131 â BioNTech expects to provide a data update from the Phase 1 trial in solid tumors in 2H 2020. SAR441000/BNT131 is partnered with Sanofi. The primary objectives will be to evaluate the safety and feasibility of administering BNT221 to patients. BNT111 â BioNTech expects to initiate this Phase 2 trial with registrational potential in the second half of 2020. ** Numbers of shares for calculating the earnings per share for the three and six months ended June 30, 2019 have been adjusted to reflect capital increase due to 1:18 share split which occurred on September 18, 2019. November 03, 2020 09:00 ET | Source: BioNTech SE. BioNTech SE (spons. Cash Position: Cash and cash equivalents as of June 30, 2020, were â¬573.0 million. The rights offering had no accounting impact within the second quarter 2020. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected cash usage for 2020 and beyond; our anticipated cash runway; the timing, completion and extent of subscription of the rights offering; the planned next steps in BioNTechâs pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of BioNTechâs product candidates; expectations for data announcements with respect to BioNTechâs clinical trials; the timing for any potential emergency use authorizations or approvals for BNT162; and our ability to scale-up manufacturing capacity for BNT162 and supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Finanzergebnisse des dritten Quartals 2020. | Text vorlesen Stop Pause Fortsetzen facebook twitter These forward-looking statements are based on BioNTechâs current expectations and speak only as of the date hereof. BioNTech: Die Quartalszahlen sind da! September 2020 endenden Quartal, der sich im Wesentlichen aus den Umsätzen der Kooperationsvereinbarungen zusammensetzte und betrug 67,5 Millionen Euro betrug (Vorjahr: 28,7 Mio). September 2020 ergab sich ein Gesamtumsatz von 136,9 Millionen Euro, verglichen mit 80,6 Mio. The increase was mainly due to an increase in headcount leading to higher wages, benefits and social security expenses as well as an increase in expenses for purchased research and development services, especially with respect to our BNT162 program. For the period of six months ended June 30, 2020, total revenue was â¬69.4 million, compared to â¬51.9 million for the comparative prior year period. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. Interim Condensed Consolidated Statements of Cash Flows, 190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png. Conference Call and Webcast InformationBioNTech SE will host a conference call and webcast today at 08:00 a.m. Der Wirkstoff-Forscher hat ordentliche Geschäftszahlen vorgelegt, die allerdings niemanden vom Hocker reißen. Adjustments to reconcile loss before tax to net cash flows: Depreciation and amortization of property, plant, equipment and intangible assets, Loss on disposal of property, plant and equipment, Decrease/(Increase) in trade receivable and contract assets, (Decrease)/Increase in trade payables, other liabilities, contract liabilities and provisions, Purchase of property, plant and equipment, Proceeds from sale of property, plant and equipment, Acquisition of subsidiaries and businesses, net of cash acquired, Proceeds from issuance of share capital, net of costs, Net increase/(decrease) in cash and cash equivalents, Change in cash resulting from exchange rate differences.
Amylin Analogs Mechanism Of Action,
Edeka Quark Magerstufe,
Garden Of Eden Where Is It Now,
So This Is Love: A Twisted Tale Audiobook,
Mt Melsungen Jugend,
Verona Food Guide,
Dekanate Erzbistum Köln,